期刊文献+

应用RP-HPLC法检测重组猪干扰素α成品蛋白含量 被引量:3

Application of RP-HPLC assay to detect the protein content of finished products of recombinant porcine interferon α
原文传递
导出
摘要 目的:建立测定重组猪干扰素α成品中蛋白含量的反相高效液相色谱法(RP-HPLC),并进行验证。方法:应用RP-HPLC法测定重组猪干扰素α标准品及供试品的蛋白含量,并对方法的线性、精密度、稳定性、重复性进行验证。采用已建立的RP-HPLC检测方法测定7批重组猪干扰素α样品的蛋白含量,与Lowry法的检测结果进行比较。结果:重组猪干扰素α在6.141 7-25μg范围内,与峰面积呈现良好的线性关系(R2=0.985 9)。用所建立的方法测定同一标准品,进样6次,计算得到RSD(相对标准偏差)为1.7%;同一批样品进样12次,检测供试品的干扰素α蛋白含量,计算得到RSD为3.9%;同一批样品,取6份分别进样,检测供试品的干扰素α蛋白含量,计算得到RSD为0.9%。结论:建立了用RP-HPLC法测定重组猪干扰素α蛋白含量的方法。该方法简便、精密度、稳定性、重复性好,将蛋白分离成单一组分峰,紫外定量测定各峰吸光度,集定量与定性、纯度检验合一,定量范围可小于10μg,测定体积只需几微升,可用于重组猪干扰素α成品蛋白含量检测。 Objective: To establish a reversed-phase high performance liquid chromatography( RP-HPLC)method to determine the protein content of finished products of recombinant porcine interferon α and verify the method. Methods: The linearity,precision,stability,and repeatability of the RP-HPLC method were verified. Then the RP-HPLC method was used to determine the protein contents of the standard substance of recombinant porcine interferon α and 7 batches of samples. The determination result was compared with that by Lowry assay. Results:The content of recombinant porcine interferon had good linear relationship with the peak area within the range of6. 141 7 ~ 25 μg( R2= 0. 985 9). The RSD of 6 injections of the same standard solution was 1. 7%,that of 12 injections of the same test sample was 3. 9%. and that of 6 samples of the same batch was 0. 9%. Conclusion: A method for determining the protein content of recombinant porcine interferon α by RP-HPLC was established. The method is simple and has good sensitivity( LOD lower than 10 μg),precision,stability,and repeatability,with small sample volume. It can be used for the protein content detection of finished products of recombinant porcine interference α.
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第13期1471-1474,共4页 Chinese Journal of New Drugs
基金 国家星火计划(2013GA710060 2014GA710014)资助项目 安徽高校省级自然科学研究重大项目(KJ2012ZD08)
关键词 重组猪干扰素α 反相高效液相色谱法 Lowry法 蛋白含量 相对标准偏差 recombinant porcine interferon α RP-HPLC Lowry assay protein content relative standard deviation(RSD)
  • 相关文献

参考文献9

  • 1ZHENG YL,ZHAO LS,WU TX,et al. Efficacy of consensus in- terferon in treatment of HBeAg-positive chronic hepatitis B: amuhicentre, randomized controlled trial [ J ]. Virol J, 2009,6 (14) :1 -6.
  • 2MIRZA S, SIDDIQUI AR, HAMID S,et al. Extent of liver inflam- mation in predicting response to interferon alpha & Ribavirin in chronic hepatitis C patients:a cohort study [ J ]. BMC Gastroen- terol,2012,12(1) :71 - 80.
  • 3AU WY, KWONG YL, MA SK, et al. Hairy cell leukemia in Hong Kong Chinese : a 12-year retrospective survey [ J ]. Hematal Onco1,2000,1 (4) :155 - 159.
  • 4王志军.生物技术药物研究开发和质量控制[M].北京:科学出版社,2002:128-135.
  • 5苏世云,夏俊保,赵俊,吴琼,王明丽.重组猪干扰素α的纯化工艺研究[J].安徽农业科学,2010,38(14):7363-7365. 被引量:7
  • 6周倩,李玉华.重组人干扰素α1b蛋白质含量HPLC检测方法的建立[J].中国生物制品学杂志,2013,26(3):419-421. 被引量:2
  • 7李永红,裴德宁,陶磊,韩春梅,饶春明.重组人干扰素α2a成品中蛋白含量体积排阻高效液相色谱法的建立[J].中国生物制品学杂志,2013,26(8):1175-1178. 被引量:6
  • 8王明丽.一种rPolFN{xl的分离纯化方法:中国,201310526225.6[P].2014-08-06.
  • 9王明丽.一种用作重组猪干扰素nl的冻干保护剂及其制备方法:中国,201310526190.6[P].2014-02-19.

二级参考文献16

  • 1TONIUTTO P,FABRIS C,PIRISI M.Antiviral treatment of hepatitis C[J].Expert Opin Pharmacother,2006,7(15):2025-2035.
  • 2TAS F,KURUL S,CAMLICA H,et al.Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma:a single institution's experience[J].Med Oncol,2006,23(4):471-477.
  • 3GATTONI A,PARLATO A,VANGIERI B,et al.Interferon-gamma:biologic functions and HCV terapy (type I/II)(2 of 2 parts)[J].Clin Ter,2006,157(5):457-468.
  • 4MARCUS P I,ROJEK J M,SEKELLICK M J.Interferon induction and/or production and its suppression by influenza A viruses[j].J Virol,2005,79(5):2880-2890.
  • 5BEILHARZ M W,CUMMINS J M,BENNETT A L.Protection from lethal influenza virus challenge by oral type 1 interferon[J].Biochem Biophys Res Commun,2007,335(3):740-744.
  • 6DUNN G P,KOEBEL C M,SCHREIBER R D.Interferons,immunity and cancer immunoediting[J].Nat Rev Immunol,2006,6(11):836-848.
  • 7J·萨姆布鲁克,D·W·拉塞尔.分子克隆实验指南[M].3版.北京:化学工业出版社,2008.
  • 8王志军.生物技术药物研究开发和质量控制[M].北京:科学出版社,2002:128-135.
  • 9Zheng Y, Zhao L, Wu T, et al. Efficacy of consensus interferon in treatment of HBeAg-positive chronic hepatitis B: a muhi- centre, randomized controlled trial [J]. Virol J, 2009, 6 (1): 99- 104.
  • 10Mirza S, Siddiqui AR, Hamid S, et al. Extent of liver inflammation in predicting response to interferon alpha & Ribavirin in chronic hepatitis C patients: a cohort study [J]. BMC Gastroenterol, 2012, 12 (1): 71-80.

共引文献14

同被引文献16

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部